Acerca de
Investor Overview
Sano Women’s Health is a clinical-stage biotechnology company developing novel therapeutics for women’s health, infectious disease, and oncology. The company’s pipeline is built around differentiated antimicrobial and higher-order actin modulating technologies designed to address diseases with significant unmet medical need, including recurrent fungal infections, drug-resistant bacterial infections, postpartum complications, and aggressive solid tumors.
Our lead clinical program, OCF001, is advancing through Phase 2 development for recurrent vulvovaginal candidiasis (RVVC), a condition affecting millions of women globally with limited effective long-term treatment options. Additional pipeline programs expand the therapeutic potential of our proprietary technologies into antibacterial and oncology indications.
Investment Highlights
Clinical-Stage Lead Asset
OCF001 is in Phase 2 development for RVVC, supported by completed Phase 1 clinical studies and FDA-cleared IND authorization.
Proprietary Platform Technologies
Our pipeline is powered by proprietary antimicrobial and HOAM (Higher-Order Actin Modulating) platform technologies with applications across infectious disease and oncology.
Multiple High-Value Indications
Programs target large and growing markets, including:
-
Recurrent vulvovaginal candidiasis (RVVC)
-
Nipple thrush and breast candidiasis
-
Drug-resistant bacterial infections
-
Postpartum mastitis and breast abscesses
-
Aggressive solid tumors
Novel Mechanisms of Action
Our therapeutic platforms utilize differentiated mechanisms designed to address limitations associated with current standards of care and antimicrobial resistance.
Platform Expansion Opportunity
The HOAM Discovery Platform provides opportunities for future pipeline expansion across antifungal, antiparasitic, and oncology indications.
Strategic Focus
Sano Women’s Health is focused on advancing first-in-class therapeutics with the potential to improve patient outcomes in diseases where innovation has remained limited. By combining clinical-stage assets with scalable discovery platforms, the company is positioned to expand across multiple therapeutic areas while leveraging shared scientific and development expertise.
CLICK IMAGE BELOW FOR A COPY OF OUR PITCH DECK FOR OUR LEAD INDICATION RVVC
